Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Neurochem ; 132(5): 532-545, 2015 03.
Artículo en Inglés | MEDLINE | ID: mdl-25345404

RESUMEN

As reported previously, in the lithium-pilocarpine model of temporal lobe epilepsy (TLE), carisbamate (CRS) produces strong neuroprotection, leads to milder absence-like seizures, and prevents behavioral impairments in a subpopulation of rats. To understand the metabolic basis of these effects, here we injected 90 mg/kg CRS or vehicle twice daily for 7 days starting 1 h after status epilepticus (SE) induction in rats. Two months later, we injected [1-13 C]glucose and [1,2-13 C]acetate followed by head microwave fixation after 15 min. 13 C incorporation into metabolites was analyzed using 13 C magnetic resonance spectroscopy. We found that SE reduced neuronal mitochondrial metabolism in the absence but not in the presence of CRS. Reduction in glutamate level was prevented by CRS and aspartate levels were similar to controls only in rats displaying absence-like seizures after treatment [CRS-absence-like epilepsy (ALE)]. Glutamine levels in CRS-ALE rats were higher compared to controls in hippocampal formation and limbic structures while unchanged in rats displaying motor spontaneous recurrent seizures after treatment (CRS-TLE). Astrocytic mitochondrial metabolism was reduced in CRS-TLE, and either enhanced or unaffected in CRS-ALE rats, which did not affect the transfer of glutamine from astrocytes to neurons. In conclusion, CRS prevents reduction in neuronal mitochondrial metabolism but its effect on astrocytes is likely key in determining outcome of treatment in this model. To understand the metabolic basis of the strong neuroprotection and reduction in seizure severity caused by carisbamate (CRS) in the lithium-pilocarpine (Li-Pilo) model of temporal lobe epilepsy (TLE), we injected CRS for 7 days starting 1 h after status epilepticus and 2 months later [1-13 C]glucose and [1,2-13 C]acetate. 13 C Magnetic resonance spectroscopy analysis was performed on brain extracts and we found that CRS prevented reduction in neuronal mitochondrial metabolism but its effect on astrocytes was likely key in determining outcome of treatment in this model. ALE = absence like epilepsy; acetyl CoA = acetyl coenzyme A; GS = glutamine synthetase; PAG = phosphate activated glutaminase; PC = pyruvate carboxylase; OAA = oxaloacetate; TCA cycle = tricarboxylic acid cycle.

2.
Epilepsia ; 55(9): 1460-8, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25059093

RESUMEN

OBJECTIVE: The Genetic Absence Epilepsy Rats from Strasbourg (GAERS) is a genetic model, derived from Wistar rats by selective breeding. In all previous studies, GAERS were compared to their paired selected strain not expressing spike-and-wave discharges (SWDs), namely nonepileptic controls (NECs). Because the occurrence/absence of SWDs is of polygenic origin, some other traits could have been selected along with occurrence/absence of SWDs. Therefore, we explored the importance of using a second control group consisting in Wistar rats, the strain of origin of GAERS, in addition to NECs, on locomotion and anxiety in GAERS. METHODS: A test battery encompassing home-cage, open-field, beam-walking and elevated plus-maze evaluations was used. In addition, stereologic analyses were performed to assess the volume of thalamus, amygdala, and hippocampus. The occurrence/absence of SWDs was determined in all three strains by electroencephalography (EEG) recording. RESULTS: When compared to NECs and Wistars, GAERS displayed lower exploratory activity and fastened habituation to novelty. In the plus-maze, scores of GAERS and Wistars were similar, but NECs appeared significantly less anxious (possibly in association with increased amygdala volume); evidence for weaker anxiety in NECs was also found in the open-field evaluation. The volumetric study revealed increased thalamic volume in GAERS compared to both control groups. SWDs were present in all GAERS and in 80% of Wistars. SIGNIFICANCE: Compared to the original Wistar strain as an additional control group, the selective breeding that generated the GAERS has no incidence on anxiety-related behavior, conversely to the selection of SWD suppression in NECs, in which anxiety is attenuated. These findings point to the importance of using a second control group composed of Wistar rats in studies characterizing the behavioral profile of GAERS. Thereby, possible confusions between occurrence/absence of SWDs and other features that come along with selection and/or differential brain development induced by the genetic mutations are reduced.


Asunto(s)
Ansiedad/etiología , Epilepsia Tipo Ausencia/complicaciones , Epilepsia Tipo Ausencia/genética , Trastornos Neurológicos de la Marcha/etiología , Análisis de Varianza , Animales , Encéfalo/patología , Ondas Encefálicas/fisiología , Modelos Animales de Enfermedad , Electroencefalografía , Conducta Exploratoria/fisiología , Locomoción/genética , Masculino , Aprendizaje por Laberinto , Desempeño Psicomotor/fisiología , Ratas , Ratas Mutantes , Ratas Wistar
3.
Epilepsia ; 55(5): 644-653, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24621352

RESUMEN

OBJECTIVE: Temporal lobe epilepsy is a relatively frequent, invalidating, and often refractory neurologic disorder. It is associated with cognitive impairments that affect memory and executive functions. In the rat lithium-pilocarpine temporal lobe epilepsy model, memory impairment and anxiety disorder are classically reported. Here we evaluated sustained visual attention in this model of epilepsy, a function not frequently explored. METHODS: Thirty-five Sprague-Dawley rats were subjected to lithium-pilocarpine status epilepticus. Twenty of them received a carisbamate treatment for 7 days, starting 1 h after status epilepticus onset. Twelve controls received lithium and saline. Five months later, attention was assessed in the five-choice serial reaction time task, a task that tests visual attention and inhibitory control (impulsivity/compulsivity). Neuronal counting was performed in brain regions of interest to the functions studied (hippocampus, prefrontal cortex, nucleus basalis magnocellularis, and pedunculopontine tegmental nucleus). RESULTS: Lithium-pilocarpine rats developed motor seizures. When they were able to learn the task, they exhibited attention impairment and a tendency toward impulsivity and compulsivity. These disturbances occurred in the absence of neuronal loss in structures classically related to attentional performance, although they seemed to better correlate with neuronal loss in hippocampus. Globally, rats that received carisbamate and developed motor seizures were as impaired as untreated rats, whereas those that did not develop overt motor seizures performed like controls, despite evidence for hippocampal damage. SIGNIFICANCE: This study shows that attention deficits reported by patients with temporal lobe epilepsy can be observed in the lithium-pilocarpine model. Carisbamate prevents the occurrence of motor seizures, attention impairment, impulsivity, and compulsivity in a subpopulation of neuroprotected rats.


Asunto(s)
Atención , Modelos Animales de Enfermedad , Epilepsia Parcial Compleja/psicología , Epilepsia del Lóbulo Temporal/psicología , Función Ejecutiva , Estado Epiléptico/psicología , Animales , Anticonvulsivantes/farmacología , Atención/efectos de los fármacos , Atención/fisiología , Encéfalo/efectos de los fármacos , Encéfalo/fisiopatología , Mapeo Encefálico , Carbamatos/farmacología , Recuento de Células , Epilepsia Parcial Compleja/inducido químicamente , Epilepsia Parcial Compleja/fisiopatología , Epilepsia del Lóbulo Temporal/inducido químicamente , Epilepsia del Lóbulo Temporal/fisiopatología , Función Ejecutiva/efectos de los fármacos , Función Ejecutiva/fisiología , Inhibición Psicológica , Carbonato de Litio , Neuronas/efectos de los fármacos , Neuronas/fisiología , Reconocimiento Visual de Modelos/efectos de los fármacos , Reconocimiento Visual de Modelos/fisiología , Pilocarpina , Ratas , Ratas Sprague-Dawley , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/fisiología , Aprendizaje Seriado/efectos de los fármacos , Aprendizaje Seriado/fisiología , Estado Epiléptico/inducido químicamente , Estado Epiléptico/fisiopatología
4.
Epilepsia ; 54(7): 1203-13, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23663139

RESUMEN

PURPOSE: Administration of carisbamate during status epilepticus (SE) prevents the occurrence of motor seizures in the lithium-pilocarpine model and leads in a subpopulation of rats to spike-and-wave discharges characteristic of absence epilepsy. Widespread neuroprotection accompanied this change in seizure expression. To assess whether these carisbamate-induced changes affected comorbidity, we used a large battery of behavioral tests in rats that had developed temporal lobe or absence-like seizures. METHODS: Lithium-pilocarpine or saline was administered to 60 adult rats. Carisbamate (90 mg/kg) or diazepam and saline was given 1 h after SE onset, and repeated 8 h later and twice daily over 6 more days. Rats were video-monitored for 2 months. Subsequently, locomotor activity, anxiety, and various types of memory were assessed. KEY FINDINGS: In rats with motor seizures, treated or not with carisbamate, all features of behavior were impaired compared to controls. Rats exhibiting absence-like seizures after carisbamate treatment behaved as controls in all paradigms tested along with widespread neuroprotection. SIGNIFICANCE: Carisbamate treatment leading to absence-like instead of temporal lobe seizures impressively prevented behavioral comorbidities reported by patients with epilepsy as the most disabling.


Asunto(s)
Anticonvulsivantes/administración & dosificación , Conducta Animal/efectos de los fármacos , Carbamatos/administración & dosificación , Estado Epiléptico/tratamiento farmacológico , Estado Epiléptico/fisiopatología , Animales , Antipsicóticos/toxicidad , Encéfalo/patología , Recuento de Células , Modelos Animales de Enfermedad , Litio/toxicidad , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Memoria/efectos de los fármacos , Fibras Musgosas del Hipocampo/efectos de los fármacos , Fibras Musgosas del Hipocampo/patología , Agonistas Muscarínicos/toxicidad , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/patología , Fosfopiruvato Hidratasa/metabolismo , Pilocarpina/toxicidad , Ratas , Ratas Sprague-Dawley , Estado Epiléptico/inducido químicamente , Estado Epiléptico/patología , Percepción Visual/efectos de los fármacos
5.
Sci Total Environ ; 654: 1146-1157, 2019 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-30841389

RESUMEN

Weirs or run-of-river dams can disrupt bedload transfer with negative ecological effects downstream due to sediment starvation. The way and the degree to which bedload is trapped is nevertheless not straightforward and few studies have examined this topic. This study focuses on a 13-km-long reservoir of the Rhône River, France, created by a diversion dam equipped with bottom gates. Our main objective was to determine the degree of alteration of the bedload transfer downstream and to identify to which extent the implementation of Ecomorphogenic Flows (EmF), defined as environmental flows whose objective is specifically to increase bedload transfer through the reservoir to promote downstream habitat diversity, could increase bed mobility. The results show that the potential for morphological adjustments in the reservoir was already low before dam completion (1968) in response to a substantial decrease in coarse sediment supply, but that this potential was progressively reduced due to the impoundment. However, the bedload transfer continuity has been at least partially maintained since dam completion. According to numerical simulations, only particles smaller than medium gravels (d < 14 mm) could be exported downstream of the dam for relatively rare discharge (50-years return-interval flood). Implementation of EmF could neatly improve the bedload transfer since it would allow to strongly increase the competence: for a 2-years and a 50-years return-interval floods, the maximum particle size exportable downstream is respectively 9 and 4 times larger than for normal the reservoir operation.

6.
Epilepsy Res ; 110: 105-14, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25616462

RESUMEN

The influence of caffeine on epileptic seizures remains a matter of debate. Here we tested on Genetic Absence Epilepsy Rats from Strasbourg (GAERS) the consequences of acute and chronic exposure to caffeine on the expression of spike-and-wave discharges (SWDs). Since caffeine is a mixed nonspecific A(1) and A(2A) adenosine receptor antagonist, we measured also the influence of antagonists and agonists of these receptors on SWD expression. GAERS were equipped with four cortical electrodes over the frontoparietal cortex and the cumulated duration and number of SWDs were recorded for 120 min after the injection of increasing doses of caffeine, specific antagonists and agonists of A(1) and A(2A) adenosine receptors. The effects of chronic caffeine were also studied. In GAERS, caffeine dose-dependently reduced the cumulated number and duration of SWDs which almost disappeared after the injection of the two highest doses of caffeine, 5 and 10 mg/kg. Likewise, the A(1) and A(2A) adenosine receptor antagonists led to a dose-dependent reduction of SWD expression while the agonists dose-dependently increased SWD expression. Conversely, the chronic exposure to caffeine via drinking water for 15 days did not influence SWD expression. With the exception of the two highest doses of caffeine that largely enhanced activity, all compounds including low doses of caffeine had no effect on locomotor activity of GAERS. These data show that the acute exposure to low doses of caffeine, or A(1) and A(2A) adenosine receptor antagonists reduces SWD expression in GAERS, independently from any effect on motor activity. The chronic exposure of GAERS to caffeine does not affect the expression of epilepsy.


Asunto(s)
Anticonvulsivantes/farmacología , Encéfalo/efectos de los fármacos , Cafeína/farmacología , Epilepsia Tipo Ausencia/tratamiento farmacológico , Agonistas Purinérgicos/farmacología , Antagonistas Purinérgicos/farmacología , Animales , Encéfalo/fisiopatología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Electrodos Implantados , Electroencefalografía , Epilepsia Tipo Ausencia/fisiopatología , Masculino , Actividad Motora/efectos de los fármacos , Ratas , Receptor de Adenosina A1/metabolismo , Receptor de Adenosina A2A/metabolismo , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológico , Convulsiones/fisiopatología , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA